Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K23 HL140482, K23 HL125723, K24 HL115354, R01 HL137006, R35 HL140026, R37 HL051856)
American Thoracic Society
Received: 30 August 2019
Accepted: 22 November 2019
First Online: 9 December 2019
Ethics approval and consent to participate
: The Molecular Epidemiology of SepsiS in the IUC (MESSI) cohort study is approved by the University of Pennsylvania Institutional Review Board. The Early Assessment of Renal and Lung Injury (EARLI) cohort study is approved by the University of California San Francisco Institutional Review Board.
: Not applicable.
: Authors NJM, MAM, CSC, and JDC receive grant support from GlaxoSmithKline to study biomarkers in sepsis. Authors AIB and ALL are employed by GlaxoSmithKline. The other authors declare that they have no competing interests.